Lucid Diagnostics Inc (LUCD NASDAQ) stock market data APIs
$1.0476
-0.02(-1.9%)
as of May 12, 2026
Try our APIs with
free plan!
Lucid Diagnostics Inc Financial Data Overview
Price chart is built with
Anychart
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Prev. Close
1.0476
Open
1.0242
High
1.0701
Low
1.0107
52 wk Range
0.9495-1.7
Market Cap
203 M
Shares Outstanding
195 M
Revenue
4 706 K
EPS
-0.1
Beta
1.104
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Lucid Diagnostics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lucid Diagnostics Inc data using free add-ons & libraries
Get Lucid Diagnostics Inc Fundamental Data
Lucid Diagnostics Inc Fundamental data includes:
- Net Revenue: 4 706 K
- EBITDA: -48 768 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-30
- EPS/Forecast: -0.0975
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lucid Diagnostics Inc News
New
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.88 per share a year ago. These figures are...
Lucid Diagnostics signals expanded VA market access and 29% sequential test volume growth while targeting Medicare and commercial payer wins
Earnings Call Insights: Lucid Diagnostics Inc. (LUCD) Q4 2025 MANAGEMENT VIEW * CEO Lishan Aklog reported that "our EsoGuard test volume in the fourth quarter was 3,664. That exceeds our target ra...
Lucid Diagnostics Inc. Q4 2025 Earnings Call Summary
Lucid Diagnostics Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Achieved record Q4 test volume of 3,664, exceeding the target range of 2,500 to 3,000, drive...
Lucid Diagnostics Q4 Earnings Call Highlights
Lucid Diagnostics logo Key Points Lucid reported fourth-quarter EsoGuard test volume of 3,664 (a 29% sequential increase) and $1.5 million in revenue, while noting a billable value of over $9 millio...
Get Lucid Diagnostics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
